➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKinsey
Medtronic
Boehringer Ingelheim
AstraZeneca

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 6,830,883

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,830,883
Title: Method for typing of minor histocompatibility antigen HA-1
Abstract:The present invention provides a method for typing of alleles of the Minor Histocompatibility Antigen HA-1 in a sample. The method comprises: a) contacting the genomic polynucleic acids in the sample with at least one pair of primers, whereby the 5.sup.1 - and/or the 3.sup.1 -primer of the at least one pair of primers specifically hybridize to target regions comprising polymorphic nucleotides in the alleles, and performing an amplification reaction; b) for each of the at least one pair of primers detecting whether or not in step a) an amplification product is formed; c) inferring from the result of step b) which HA-1 allele is present in the sample. The present invention also provides a method for genomic typing of alleles of the Minor Histocompatibility Antigen HA-1 in a sample. This method comprises: a) amplifying a fragment of the alleles, with the fragment comprising at least one polymorphic nucleotide, by use of at least one pair of primers specifically hybridizing to conserved target region comprising one or more polymorphic nucleotides in the allele; c) inferring from the result of step b) which HA-1 allele is present in the sample. In addition, the present invention provides primers and probes for use in the above-mentioned methods. Diagnostic kits enabling the methods are also provided.
Inventor(s): Goulmy; Elsa Afra Julia Maria (Oegstgeest, NL)
Assignee: Rijksuniversiteit Leiden (NL)
Application Number:09/269,250
Patent Claims:see list of patent claims

Details for Patent 6,830,883

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Rijksuniversiteit Leiden (NL) 2017-07-23 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Rijksuniversiteit Leiden (NL) 2017-07-23 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Rijksuniversiteit Leiden (NL) 2017-07-23 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Express Scripts
Mallinckrodt
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.